Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom
Crossref DOI link: https://doi.org/10.1007/s10198-017-0879-5
Published Online: 2017-03-08
Published Print: 2018-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wilson, Michele R.
Bergman, Annika
Chevrou-Severac, Helene
Selby, Ross
Smyth, Michael
Kerrigan, Matthew C.
Funding for this research was provided by:
Takeda Pharmaceuticals AG (N/A)
License valid from 2017-03-08